Uhlyarik, A.; Piurko, V.; Papai, Z.; Raso, E.; Lahm, E.; Kiss, E.; Sikter, M.; Vachaja, J.; Kenessey, I.; Timar, J.
EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy. Cancers 2020, 12, 614.
https://doi.org/10.3390/cancers12030614
AMA Style
Uhlyarik A, Piurko V, Papai Z, Raso E, Lahm E, Kiss E, Sikter M, Vachaja J, Kenessey I, Timar J.
EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy. Cancers. 2020; 12(3):614.
https://doi.org/10.3390/cancers12030614
Chicago/Turabian Style
Uhlyarik, Andrea, Violetta Piurko, Zsuzsanna Papai, Erzsebet Raso, Erika Lahm, Edina Kiss, Marta Sikter, Jozsef Vachaja, Istvan Kenessey, and Jozsef Timar.
2020. "EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy" Cancers 12, no. 3: 614.
https://doi.org/10.3390/cancers12030614
APA Style
Uhlyarik, A., Piurko, V., Papai, Z., Raso, E., Lahm, E., Kiss, E., Sikter, M., Vachaja, J., Kenessey, I., & Timar, J.
(2020). EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy. Cancers, 12(3), 614.
https://doi.org/10.3390/cancers12030614